株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膵臓癌 (膵癌):パイプライン製品の分析

Pancreatic Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200987
出版日 ページ情報 英文 2006 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.66円で換算しております。
Back to Top
膵臓癌 (膵癌):パイプライン製品の分析 Pancreatic Cancer - Pipeline Review, H2 2016
出版日: 2016年12月28日 ページ情報: 英文 2006 Pages
概要

膵臓癌膵臓癌 (膵癌) とは、膵臓の組織に悪性細胞(癌細胞)が発生するという疾患で、外分泌系癌とも呼ばれています。主な徴候・症状として、上腹部痛やその背中への拡散、黄疸、食欲不振、体重減少、うつ、血餅などが挙げられます。主な疾病素質には年齢や性別、喫煙、糖尿病、家族歴などがあります。主な治療法には、外科手術、化学療法、放射線治療などが含まれています。

当レポートでは、世界各国での膵臓癌膵臓癌 (膵癌) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

膵臓癌の概要

治療薬の開発

膵臓癌:企業で開発中の治療薬

膵臓癌:大学/機関で研究中の治療薬

膵臓癌:パイプライン製品の概況

膵臓癌:企業で開発中の製品

膵臓癌:大学/機関で研究中の製品

膵臓癌の治療薬開発に従事している企業

膵臓癌:治療薬の評価

薬剤プロファイル

膵臓癌:休止中のプロジェクト

膵臓癌:開発が中止された製品

膵臓癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8862IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Cancer Overview
  • Therapeutics Development
  • Pancreatic Cancer - Therapeutics under Development by Companies
  • Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
  • Pancreatic Cancer - Pipeline Products Glance
  • Pancreatic Cancer - Products under Development by Companies
  • Pancreatic Cancer - Products under Investigation by Universities/Institutes
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Drug Profiles
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pancreatic Cancer, H2 2016
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Development by Companies, H2 2016 (Contd..21)
  • Number of Products under Development by Companies, H2 2016 (Contd..22)
  • Number of Products under Development by Companies, H2 2016 (Contd..23)
  • Number of Products under Development by Companies, H2 2016 (Contd..24)
  • Number of Products under Development by Companies, H2 2016 (Contd..25)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Development by Companies, H2 2016 (Contd..33)
  • Products under Development by Companies, H2 2016 (Contd..34)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Pancreatic Cancer - Pipeline by 4SC AG, H2 2016
  • Pancreatic Cancer - Pipeline by AB Science SA, H2 2016
  • Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016
  • Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016
  • Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016
  • Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016
  • Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016
  • Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016
  • Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016
  • Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016
  • Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016
  • Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016
  • Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016
  • Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016
  • Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016
  • Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016
  • Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016
  • Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016
  • Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
  • Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Pancreatic Cancer - Pipeline by Bayer AG, H2 2016
  • Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Berg LLC, H2 2016
  • Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016
  • Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
  • Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016
  • Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016
  • Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016
  • Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016
  • Pancreatic Cancer - Pipeline by Biotest AG, H2 2016
  • Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016
  • Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016
  • Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016
  • Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016
  • Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Celyad SA, H2 2016
  • Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016
  • Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016
  • Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016
  • Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016
  • Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016
  • Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016

List of Figures

  • Number of Products under Development for Pancreatic Cancer, H2 2016
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top